肝转移治疗市场 - 按药物类别（标靶治疗、化疗、免疫治疗）、原发性癌症（结直肠癌、乳癌、肺癌）、配销通路（医院药房、专业药房）、全球预测（2024 - 2032 ）

Liver Metastases Treatment Market - By Drug Class (Targeted Therapy, Chemotherapy, Immunotherapy), Primary Cancer (Colorectal, Breast, Lung), Distribution Channel (Hospital Pharmacies, Specialty Pharmacies), Global Forecast (2024 - 2032)

出版日期: 2024年05月22日 | 出版商:

Global Market Insights Inc. | 英文 114 Pages | 商品交期: 2-3个工作天内

价格

简介目录

受大肠直肠癌和乳癌等通常转移至肝臟的原发性癌症发生率上升的推动，2024年至2032年全球肝转移治疗市场的复合年增长率将超过6.7%。根据美国癌症协会的数据，2023 年美国将诊断出约 149,500 例结直肠癌新病例和 297,790 例乳腺癌新病例。免疫疗法和微创手术技术，可改善患者的治疗效果并减少副作用。

此外，医疗保健支出的增加、人们对早期诊断和治疗重要性的认识不断提高以及专业医疗保健服务的不断扩大，正在进一步推动市场成长。製药公司正在大力投资研发以推出新疗法，而有利的监管政策正在加快新疗法的审批流程。这些因素共同塑造了市场动态。

肝转移治疗市场根据药物类别、原发癌症、配销通路和地区进行分类。

由于标靶肝转移的功效以及药物配方和递送机制的进步，到 2032 年，化疗领域将经历显着的复合年增长率。化疗药物在控制肿瘤生长和延长患者存活率方面显示出显着改善。更个人化和有针对性的化疗方案的开发提高了治疗效果并减少了副作用，使这些药物成为治疗肝转移的首选。

由于乳癌患者转移进展发生率不断增加，到 2032 年，乳癌细分市场将占据显着的肝转移治疗市场。随着早期发现和治疗提高存活率，越来越多的患者能够活到癌症转移到肝臟的程度。这凸显了对针对肝转移的有效治疗的更大需求。此外，个人化医疗和标靶治疗的进步进一步提高了乳癌肝转移的治疗效果。

由于人口老化和癌症发生率上升，欧洲肝转移治疗产业在预测期内将录得良好的复合年增长率。医疗保健基础设施的增强和先进医疗技术的普及提高了诊断能力，从而实现更早的检测和更有效的治疗选择。该地区的医疗保健政策着重于个人化治疗方法，刺激了创新疗法的采用。癌症研发资金的增加有助于提供新的和改进的治疗方式，从而促进区域市场的成长。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AstraZeneca
Bayer AG
Bristol-Myers Squibb Company
Cadila Pharmaceuticals Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Novartis AG
Ono Pharmaceutical
Pfizer, Inc.

简介目录

Product Code: 9582

Global Liver Metastases Treatment Market will register over 6.7% CAGR from 2024 to 2032, driven by the rising incidence of primary cancers, such as colorectal and breast cancer, which commonly metastasize to the liver. According to the American Cancer Society, approximately 149,500 new cases of colorectal cancer and 297,790 new cases of breast cancer were diagnosed in the United States in 2023. Advancements in medical technology and oncology research have led to the development of innovative treatment modalities, including targeted therapies, immunotherapies, and minimally invasive surgical techniques, which offer improved patient outcomes and reduced side effects.

Additionally, increasing healthcare expenditure, growing awareness about the importance of early diagnosis and treatment, and the expanding availability of specialized healthcare services are further propelling market growth. Pharmaceutical companies are investing heavily in R&D to introduce novel therapies, while favorable regulatory policies are accelerating the approval process for new treatments. These factors combinedly shape the market dynamics.

The liver metastases treatment market is sorted based on drug class, primary cancer, distribution channel, and region.

The chemotherapy segment will experience a remarkable CAGR through 2032, because of efficacy in targeting liver metastases, linked with advancements in drug formulations and delivery mechanisms. Chemotherapy drugs have shown significant improvements in controlling tumor growth and extending patient survival rates. The development of more personalized & targeted chemotherapy options has enhanced treatment outcomes and reduced side effects, making these drugs a preferred choice in managing liver metastases.

The breast cancer segment will clutch a notable liver metastases treatment market share by 2032, owing to the increasing incidence of metastatic progression in breast cancer patients. As survival rates improve with early detection and treatment, a higher number of patients are living long enough for their cancer to metastasize to the liver. This highlights a greater need for effective treatments targeting liver metastases. Additionally, advancements in personalized medicine and targeted therapies have further enhanced treatment efficacy for breast cancer led liver metastases.

Europe liver metastases treatment industry will record a promising CAGR during the forecast period, because of the aging population and increased cancer incidence rates. Enhanced healthcare infrastructure and access to advanced medical technologies have improved diagnostic capabilities, leading to earlier detection and more effective treatment options. The healthcare policies of the region focus on personalized treatment approaches, spurring the adoption of innovative therapies. Increased funding for cancer R&D contributes to the availability of new and improved treatment modalities, thus augmenting the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing incidence of cancer
  - 3.2.1.2 Advancements in treatment modalities
  - 3.2.1.3 Increasing awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Side effects associated with medications
  - 3.2.2.2 Stringent regulatory scenarios
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Targeted therapy drugs
5.3 Chemotherapy drugs
5.4 Immunotherapy drugs

Chapter 6 Market Estimates and Forecast, By Primary Cancer, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Colorectal cancer
6.3 Breast cancer
6.4 Lung cancer
6.5 Other cancers

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospital pharmacies
7.3 Specialty pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa